Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Early clearance for R-B, Adams

This article was originally published in The Tan Sheet

Executive Summary

Slough, U.K.-based Reckitt Benckiser on Jan. 8 announced the receipt of an early termination of the waiting period under the Hart-Scott-Rodino Act regarding its offer to purchase all outstanding shares of Adams Respiratory Therapeutics' stock. Through its wholly owned subsidiary Twickenham, Reckitt, a household cleaning, health and personal care product firm, made an offer in December to purchase all Chester, N.J.-based Adams' outstanding stock for $60 per share (1"The Tan Sheet" Dec. 17, 2007, p. 5)...

You may also be interested in...



Reckitt Benckiser Looks Overseas To Double Adams’ Revenue

Reckitt Benckiser should meet its goal of doubling Adams Respiratory Therapeutics' revenues by launching the firms' OTC cough and congestion products overseas and introducing new products being developed by Adams in the United States, analysts and Reckitt executives say

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

The rulemaking is supposed to formalize the Patent Trial and Appeal Board process, which has been in an interim status since a Supreme Court decision, giving manufacturers more ability to request oversight of the decisions. 

It’s Been Over 1100 Days Since MCIT, Still No TCET In Sight

AdvaMed’s new online clock documents the time since CMS promised to replace MCIT, a program guaranteeing coverage for FDA-cleared breakthrough devices.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101244

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel